SCHEMBL3563997

SCHEMBL3563997

Cc1[nH]c2cc(Cl)ccc2c1OCCN(C)C

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRA2A P08913 1/20 0.50
ADRA2B P18089 1/20 0.50
ADRA2C P18825 1/20 0.50
HTR7 P34969 1/20 0.50
HTR2B P41595 1/20 0.50
HTR6 P50406 1/20 0.50
ACHE P22303 1/20 0.47
MAOA P21397 1/20 0.43
MAPT P10636 1/20 0.43
SLC6A4 P31645 1/20 0.43
PTGS1 P23219 2/20 0.43
PTGS2 P35354 2/20 0.43
MPO P05164 1/20 0.43
XDH P47989 1/20 0.43
CHRNB2 P17787 1/20 0.41
CHRNA4 P43681 1/20 0.41
NR4A2 P43354 2/20 0.41
TP53 P04637 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
KDM4E B2RXH2 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3563207 0.89 HTR7 (0.60) ADRA2AADRA2BADRA2CHTR7HTR2B
SCHEMBL3555171 0.81 PDE10A (0.50) HTR7HTR6ACHESLC6A4KDM4E
SCHEMBL3556246 0.80 HTR6 (0.56) HTR7HTR6ACHEMAPTMPO
SCHEMBL3561474 0.78 MAPT (0.46) ADRA2AADRA2BADRA2CHTR7HTR2B
SCHEMBL8923426 0.77 CYP1A2 (0.48) KDM4E
SCHEMBL3564365 0.75 SLC6A4 (0.43) ADRA2AADRA2BADRA2CHTR7HTR2B
SCHEMBL10692528 0.75 MAPT (0.49) ADRA2AADRA2BADRA2CHTR2BACHE
SCHEMBL13438413 0.75 ACHE (0.53) ACHEMAOAMAPTMPOXDH
SCHEMBL3460311 0.74 ADRA2A (0.49) ADRA2AADRA2BADRA2CHTR7HTR2B
SCHEMBL3555772 0.74 HTR6 (0.64) HTR7HTR2BHTR6MAPTSLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1567492-B1 N-ARYLSULFONYL-3-AMINOALKOXYINDOLES SUVEN LIFE SCIENCES LTD (IN) 2013-05-22 EP disclosed
US-7718690-B2 N-arylsulfonyl-3-aminoalkoxyindoles RAMAKRISHNA VENKATA SATYA NIROGI 2010-05-18 US disclosed
US-20090131507-A1 N-arylsulfonyl-3-aminoalkoxyindoles SUVEN LIFE SCIENCES LIMITED (IN) 2009-05-21 US disclosed
EP-1567492-A2 N-ARYLSULFONYL-3-AMINOALKOXYINDOLES Suven Life Sciences Limited (IN) 2005-08-31 EP disclosed
WO-2004048328-A2 N-ARYLSULFONYL-3-AMINOALKOXYINDOLES SUVEN LIFE SCIENCES LIMITED (IN) 2004-06-10 WO disclosed
WO-2004048331-A1 N-ARYLALKYL-3-AMINOALKOXYINDOLES AND THEIR USE AS 5-HT LIGANDS SUVEN LIFE SCIENCES LIMITED (IN) 2004-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131507-A1 N-arylsulfonyl-3-aminoalkoxyindoles HTR3C, HTR3A, AANAT ADRA2A 50/4885ADRA2B 84/4885ADRA2C 28/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.